Cargando…

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity

SIMPLE SUMMARY: Antibodies with their high specificity to antigens have been widely used in cancer immunotherapy. Natural killer (NK) cells are a group of innate immune cells which have strong cytotoxicity against cancerous cells, virus infected cells, or transformed cells. NK cells express abundant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gong, Ying, Klein Wolterink, Roel G. J., Gulaia, Valeriia, Cloosen, Silvie, Ehlers, Femke A. I., Wieten, Lotte, Graus, Yvo F., Bos, Gerard M. J., Germeraad, Wilfred T. V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8197514/ https://www.ncbi.nlm.nih.gov/pubmed/34070311 http://dx.doi.org/10.3390/cancers13112579

Ejemplares similares

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

P1368: NKG2A DELETION IN HUMAN NATURAL KILLER CELLS ENHANCES ANTI-TUMOR RESPONSES AND PROMOTES TUMOR INFILTRATION
por: Gong, Ying, et al.
Publicado: (2023)

Hypoxia Induced Impairment of NK Cell Cytotoxicity against Multiple Myeloma Can Be Overcome by IL-2 Activation of the NK Cells
por: Sarkar, Subhashis, et al.
Publicado: (2013)

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages
por: Ehlers, Femke A. I., et al.
Publicado: (2023)

Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor
por: Gong, Ying, et al.
Publicado: (2020)

Influence of Vitamin C on Lymphocytes: An Overview
por: van Gorkom, Gwendolyn N. Y., et al.
Publicado: (2018)

Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A
por: Mahaweni, Niken M., et al.
Publicado: (2018)

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

Defucosylated Mouse–Dog Chimeric Anti-EGFR Antibody Exerts Antitumor Activities in Mouse Xenograft Models of Canine Tumors
por: Li, Guanjie, et al.
Publicado: (2021)

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment
por: Mahaweni, Niken M., et al.
Publicado: (2018)

Defucosylated mouse-dog chimeric anti-HER2 monoclonal antibody exerts antitumor activities in mouse xenograft models of canine tumors
por: Suzuki, Hiroyuki, et al.
Publicado: (2022)

First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors
por: Shitara, Kohei, et al.
Publicado: (2019)

Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models
por: Li, Guanjie, et al.
Publicado: (2023)

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy
por: Beelen, Nicky A., et al.
Publicado: (2022)

HLA Class I Molecules as Immune Checkpoints for NK Cell Alloreactivity and Anti-Viral Immunity in Kidney Transplantation
por: Duygu, Burcu, et al.
Publicado: (2021)

CD16 pre-ligation by defucosylated tumor-targeting mAb sensitizes human NK cells to γ(c) cytokine stimulation via PI3K/mTOR axis
por: Capuano, Cristina, et al.
Publicado: (2020)

Killing the Invaders: NK Cell Impact in Tumors and Anti-Tumor Therapy
por: Molgora, Martina, et al.
Publicado: (2021)

Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients
por: Ehlers, Femke A. I., et al.
Publicado: (2021)

Structural basis for improved efficacy of therapeutic antibodies on defucosylation of their Fc glycans
por: Mizushima, Tsunehiro, et al.
Publicado: (2011)

An anti-MUC1-antibody–interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells
por: Heuser, C, et al.
Publicado: (2003)

Effect of MUC1 Mucin, an Anti‐adhesion Molecule, on Tumor Cell Growth
por: Makiguchi, Yusuke, et al.
Publicado: (1996)

Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors
por: Harada, Takeshi, et al.
Publicado: (2013)

The anti-inflammatory mechanisms of Hsp70
por: Borges, Thiago J., et al.
Publicado: (2012)

MUC1 promotes lung metastases of liver cancer by impairing anti-tumor immunity
por: Yin, Yanze, et al.
Publicado: (2023)

Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice
por: Curry, Jennifer M., et al.
Publicado: (2019)

“Stealth” tumors: Breast cancer cells shun NK-cells anti-tumor immunity
por: Mamessier, Emilie, et al.
Publicado: (2012)

MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
por: Gubbels, Jennifer AA, et al.
Publicado: (2010)

Pathogen recognition by NK cells amplifies the pro-inflammatory cytokine production of monocyte-derived DC via IFN-γ
por: Oth, Tammy, et al.
Publicado: (2018)

Revisiting the Prominent Anti-Tumoral Potential of Pre-mNK Cells
por: Guimont-Desrochers, Fanny, et al.
Publicado: (2013)

Combination Immune Therapies to Enhance Anti-Tumor Responses by NK Cells
por: Mentlik James, Ashley, et al.
Publicado: (2013)

Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer
por: Greppi, Marco, et al.
Publicado: (2019)

Augmentation of antitumour activity of defucosylated chimeric anti-CCR4 monoclonal antibody in SCID mouse model of adult T-cell leukaemia/lymphoma using G-CSF
por: Yano, Hiroki, et al.
Publicado: (2008)

A Defucosylated Anti-EpCAM Monoclonal Antibody (EpMab-37-mG(2a)-f) Exerts Antitumor Activity in Xenograft Model
por: Asano, Teizo, et al.
Publicado: (2022)

PD-L1 blockade enhances anti-tumor efficacy of NK cells
por: Oyer, Jeremiah L., et al.
Publicado: (2018)

Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma
por: Rennert, Charlotte, et al.
Publicado: (2021)

NK Cell Anti-Tumor Surveillance in a Myeloid Cell-Shaped Environment
por: Russo, Eleonora, et al.
Publicado: (2021)

Cytokine engineered NK-92 therapy to improve persistence and anti-tumor activity
por: Shin, Hyun Young, et al.
Publicado: (2023)

IL-1R8 is a checkpoint in NK cells regulating anti-tumor and anti-viral activity
por: Molgora, Martina, et al.
Publicado: (2017)

Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas
por: Zuo, Pengcheng, et al.
Publicado: (2023)

MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice
por: Yang, Ming, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_j2f19prj1lbfcn1num7r05cmb8